Integrin β1/LRRC15 exerts a metastatic invasion role via activation of FAK in patient-derived ovarian cancer xenograft models, inhibited by ABBV-085, an antibody–drug conjugate of LRRC15 (195). The gene discussed is PTK2; the disease is ovarian carcinoma.